• Rhelion Life Sciences' subsidiary Filament Health shipped botanical psilocybin candidate PEX010 to King's College London for its SLEEPY feasibility study.
• The study will evaluate dosing healthy volunteers just before sleep to prevent participants from knowing whether they received psilocybin.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhelion Life Sciences Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202611090731NEWSFILECNPR____20261109_323095_1) on November 09, 2026, and is solely responsible for the information contained therein.